Alzheimer's intervention is moving upstream: trials now enroll cognitively normal adults identified by amyloid and tau biomarkers rather than patients with established cognitive impairment. The premise is that disrupting pathology during the decades-long preclinical phase may prevent symptom onset altogether, a departure from decades of trials in symptomatic disease that produced marginal benefit.
Key Points
- Prevention trials now enroll cognitively normal, biomarker-positive adults
- Amyloid and tau accumulate decades before symptoms appear
- Late-stage intervention has consistently yielded limited clinical benefit
Longevity Analysis
Cognitive decline follows a trajectory set in motion long before diagnosis, which makes risk stratification in midlife more consequential than any intervention offered after memory loss. Blood-based biomarkers, genotyping, and imaging now allow that trajectory to be read early, at the same stage where vascular health, metabolic control, sleep quality, and the brain's overnight clearance of metabolic waste remain modifiable. The practical implication is a shift in emphasis toward sustained, decades-long management of modifiable risk alongside whatever pharmacologic prevention proves effective.
Original published by Peter Attia MD, by Peter Attia.